Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
L01EH03 Tucatinib
D11141 Tucatinib (USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors
Tucatinib
D11141 Tucatinib (USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03158 HER2 inhibitor
DG03240 Tucatinib
D11141 Tucatinib
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG03240 Tucatinib
D11141 Tucatinib
DG01633 CYP3A/CYP3A4 substrate
DG03240 Tucatinib
D11141 Tucatinib
Drug classes [BR:br08332]
Antineoplastic
DG03158 HER2 inhibitor
D11141 Tucatinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
D11141 Tucatinib (USAN/INN) <US>
ERBB3 (HER3)
D11141 Tucatinib (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11141
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11141
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11141
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11141
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11141
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03158 HER2 inhibitor
DG03240 Tucatinib
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG03240 Tucatinib
DG01633 CYP3A/CYP3A4 substrate
DG03240 Tucatinib